Browsing by Author "Argudo Campos, Jennifer Michelle"

Now showing 1 - 3 of 3

Asociación hiperglucemia postoperatoria con complicaciones postoperatorias. Pacientes mayores de 40 años. Hospital José Carrasco Arteaga - 2019
(Universidad de Cuenca, 2021-07-16) Andrade Novillo, María Camila; Argudo Campos, Jennifer Michelle; Jiménez Encalada, Marcia Gabriela; Roldán Fernández, José Vicente
The American Diabetes Association recognizes that a postoperative hyperglycemia greater than or equal to 180 mg/dL is associated with an increased rate of postoperative infections and hospitalization costs. Preoperative and postoperative hyperglycemia are a negative but modifiable factor for the patient after surgery patients. OBJECTIVE To determine the association between postoperative hyperglycemia and complications in patients older than 40 years at the José Carrasco Arteaga Hospital in 2019. METHODS AND MATERIALS An observational, analytic, transversal, retrospective study was conducted, including clinical histories of patients 40 years and above who entered general surgery at the José Carrasco Arteaga Hospital in 2019. The data collected with Epi Info forms was analyzed and codified with IBM SPSS V.25 educational license, using number, frequencies and percentage, arithmetic mean and standard deviation. In the analysis of bivariate data, we used the Chi-square to estimate statistically significant differences when p < 0.05. The prevalence ratio with a 95% confidence interval was used to determine the association between variables. RESULTS We found a mean of 64 years (13 years); 55,1% of the participants are of masculine gender. The prevalence of preoperative hyperglycemia was 28,1% and of postoperative hyperglycemia was 11,5%. A statistically significant association was found between postoperative complications and masculine gender (p 0.008), the presence of comorbidities (p 0.000), preoperative hyperglycemia (p 0.000) and postoperative hyperglycemia (p 0.003). CONCLUSIONS A statistically significant association was found between postoperative complications and masculine gender, the presence of comorbidities, preoperative hyperglycemia and postoperative hyperglycemia (p 0.003).
Relevance of fluorodopa PET scan in dopamine responsive dystonia and juvenile parkinsonism: a systematic review
(2022) Argudo Campos, Jennifer Michelle
Background: Dopamine Responsive Dystonia (DRD) and Juvenile Parkinsonism (JP) are two diseases commonly presenting with parkinsonian symptoms in young patients. Current clinical guidelines offer a diagnostic approach based on molecular analysis. However, developing countries have limitations in terms of accessibility to these tests. We aimed to assess the utility of imaging equipment, usually more available worldwide, to help diagnose and improve patients’ quality of life with these diseases. Methods: We performed a systematic literature review in English using the preferred reporting items for systematic reviews and meta-analyses (PRISMA) and meta-analysis of observational studies in epidemiology (MOOSE) protocols. We only used human clinical trials about dopamine responsive dystonia and juvenile parkinsonism patients in which a fluorodopa (FD) positron emission tomography (PET) scan was performed to identify its use in these diseases. Results: We included six studies that fulfilled our criteria. We found a clear pattern of decreased uptake in the putamen and caudate nucleus in JP cases. At the same time, the results in DRD were comparable to normal subjects, with only a slightly decreased marker uptake in the previously mentioned regions by the FD PET scan. Conclusions: We found a distinctive pattern for each of these diseases. Identifying these findings with FD PET scans can shorten the delay in making a definitive diagnosis when genetic testing is unavailable, a common scenario in developing countries.
Use of riluzole for the treatment of hereditary ataxias: a systematic review
(2022) Argudo Campos, Jennifer Michelle
Ataxia is a constellation of symptoms that involves a lack of coordination, imbalance, and difficulty walking. Hereditary ataxia occurs when a person is born with defective genes, and this degenerative disorder may progress for several years. There is no effective cure for ataxia, so we need to search for new treatments. Recently, interest in riluzole in the treatment of ataxia has emerged. We conducted this systematic review to analyze the safety and efficacy of riluzole for treating hereditary ataxia in recent clinical trials. We conducted a systematic review using PubMed and Google Scholar as databases in search of this relationship. We used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Meta-analysis of Observational Studies in Epidemiology (MOOSE) protocols to conduct this study. For inclusion criteria, we included full-text clinical trials on humans written in English and found three clinical trials. We excluded case reports, literature reviews, systematic reviews, and meta-analyses for this analysis. We aimed to evaluate the Scale for the Assessment and Rating of Ataxia (SARA) score, the International Cooperative Ataxia Rating Scale (ICARS) score, and the safety of the medication. Two out of the three clinical trials showed statistically significant clinical improvement in the ICARS and SARA scores, while the other trial did not show improvement in the clinical or radiological outcomes. The drug was safe in all clinical trials. Overall, the results of this analysis of riluzole for the treatment of hereditary ataxia are encouraging. Further clinical trials are needed to investigate the efficacy of riluzole on hereditary ataxia.